VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 3, 2008) - Med BioGene Inc. (TSX VENTURE:MBI), a life science company focused on the development and commercialization of genomic-based diagnostic tests for cancer and cardiovascular disease, today announced results from a recent study that confirm the previously demonstrated high accuracy rate of LymphExpress DxTM v.1.0.
